Oral Semaglutide Explained: How the GLP-1 Pill Works

For most of their history, GLP-1 weight-loss medicines meant needles. Semaglutide, the active ingredient in the best-known weekly pens, is a peptide: a small protein. Proteins are exactly what your stomach is built to break down, so swallowing one as a pill should, in theory, not work at all.

Oral semaglutide is the exception. It is the same molecule as the injection, packed into a tablet with a helper ingredient that lets enough of it slip through the stomach wall to matter. Since the FDA approved the Wegovy pill for weight management in December 2025, it has become one of the most talked-about options for people who want GLP-1 treatment without injections.

This guide explains how the pill works, what the label asks you to do every morning and why, what the main trial found, how side effects compare with the shot, and how oral semaglutide differs from other GLP-1 pills.

Educational only. This is not medical advice. Whether any weight-loss medicine is right for you, and which form, is a decision to make with a licensed clinician who knows your health history.

What is oral semaglutide?

Oral semaglutide is semaglutide, a GLP-1 receptor agonist, formulated as a tablet you swallow once a day instead of an injection. Each tablet combines semaglutide with an absorption enhancer called salcaprozate sodium (SNAC), which protects the drug in the stomach and helps it cross into the bloodstream.

Two oral semaglutide products are approved in the US:

• Wegovy pill (semaglutide tablets, maintenance dose 25 mg daily), approved December 22, 2025, to reduce excess body weight and keep it off long term in adults with obesity, or adults with overweight plus at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. It is also approved to reduce the risk of major cardiovascular events (cardiovascular death, heart attack or stroke) in adults with established heart disease and either obesity or overweight.
• Rybelsus (semaglutide tablets), approved earlier to improve blood sugar control in adults with type 2 diabetes. It uses the same SNAC technology at lower doses and is not approved for weight management.

When Novo Nordisk announced the approval in a filing with the US Securities and Exchange Commission, it described the Wegovy pill as “the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management.” A second, chemically different GLP-1 pill, Foundayo (orforglipron), followed in April 2026; more on that below.

If GLP-1s are new to you, start with what a GLP-1 medication is and what semaglutide is, then come back here.

How does a peptide pill survive the stomach?

This is the clever part, and it explains almost every rule on the label.

The problem: proteins get digested

Your stomach is acidic and full of enzymes such as pepsin, which chop proteins into pieces. Even an intact peptide is large and does not pass easily through the cells lining the gut. That is why insulin, another peptide, has always been injected.

The fix: SNAC, a local bodyguard

Researchers at Novo Nordisk described how oral semaglutide is absorbed in a 2018 paper in Science Translational Medicine. Using studies in dogs and people, they found something unusual: unlike most pills, which are absorbed in the small intestine, oral semaglutide is absorbed in the stomach, in a small area right next to where the tablet dissolves, and only when it is formulated together with SNAC.

A 2024 review of SNAC summarizes three ways it helps:

1. It buffers the acid locally. SNAC raises the pH in the tiny zone around the dissolving tablet, which protects semaglutide from being broken down by stomach enzymes.
2. It keeps semaglutide molecules separate. SNAC reduces clumping of semaglutide molecules, which could otherwise hinder absorption.
3. It briefly loosens cell membranes. SNAC interacts with the fatty membranes of stomach-lining cells, making them temporarily more permeable so semaglutide can pass through the cells themselves. The 2018 paper found no evidence that it opens the “tight junctions” between cells.

The effect is temporary and reversible. The review notes that permeability heads back toward baseline from about 30 minutes after exposure.

Even then, only a sliver gets in

The Wegovy label puts the absolute bioavailability of oral semaglutide at roughly 1% to 2%. In other words, nearly all of each tablet’s semaglutide never reaches your blood. That is why the oral dose (25 mg a day) is so much larger than the injected dose (2.4 mg a week), and why small changes in how you take the pill can matter.

Once it is absorbed, semaglutide behaves the same way it does after an injection. It binds to albumin in the blood, which protects it from rapid breakdown, and has a half-life of about one week. That long half-life is what lets a daily pill build up steady levels. To understand what semaglutide then does to appetite and the brain, see how GLP-1s work for weight loss.

How to take the Wegovy pill: the morning routine, explained

The label instructions are strict, and each one maps directly onto the absorption science above. Here is what the FDA label says, and why.

Label instruction	Why it matters
Take one tablet once daily, in the morning, on an empty stomach	Food in the stomach interferes with the small absorption zone around the tablet.
Take it with water only, up to 4 ounces (about half a cup). No other liquids	In a label study, absorption was higher with about 50 mL of water than with 240 mL. Coffee, juice and milk are not plain water.
Swallow whole. Do not split, crush, chew or dissolve	Absorption depends on the tablet dissolving in place alongside its SNAC.
Wait at least 30 minutes before food, drinks or other oral medicines	In a 10-day label study, absorption was higher with longer fasting periods after the dose.
Do not take more than one tablet a day	Doubling up does not make up for a missed day.

The label describes these as general instructions; your prescriber and pharmacist may give you more detail for your situation, so follow what they tell you.

Practical tips people use

Doctors who make patient videos tend to repeat the same advice: build the pill into a fixed wake-up routine. In a short YouTube explainer, Dr. Alicia Shelly, a physician who posts patient-education videos, stresses taking it first thing on a completely empty stomach with 4 ounces of plain water, not alongside other medicines, “especially your thyroid medication,” then waiting 30 minutes before eating or drinking.

Habits that can help, as long as they fit your prescriber’s instructions:

• Keep the bottle and a small glass where you will see it when you wake up.
• Use the 30-minute wait for a shower, getting dressed or a short walk.
• Ask your pharmacist to review every morning medicine and supplement you take, and to help you schedule them around the pill.
• If you drink coffee first thing, plan it for after the waiting period.

What if you miss a dose?

The Wegovy label is simple here: skip the missed dose and take the next dose the following day. Do not take two tablets.

The label’s dose schedule

Like the injection, the pill starts low and steps up to reduce digestive side effects. The label’s schedule is 1.5 mg daily for days 1 to 30, 4 mg for days 31 to 60, 9 mg for days 61 to 90, and the 25 mg maintenance dose from day 91 onward. The label lets clinicians delay a step if a dose is not tolerated. Your prescriber decides your doses and timing, so treat this as background, not a plan.

What the research shows: OASIS 4

The Wegovy pill’s weight-management approval rests mainly on OASIS 4, a phase 3 trial published in the New England Journal of Medicine in 2025 (Wharton et al.), plus supporting data from the semaglutide injection program and the SELECT heart outcomes trial.

The trial in brief

• Who: 307 adults with a BMI of 30 or higher, or 27 or higher with at least one obesity-related condition. People with type 2 diabetes were excluded. Average age was 48, 79% were women, and average starting weight was about 106 kg (roughly 234 lb).
• Design: double-blind and placebo-controlled at 22 sites in four countries. Participants were randomly assigned 2:1 to oral semaglutide 25 mg or a placebo tablet, both alongside lifestyle support.
• Length: 64 weeks of treatment, including a 12-week dose escalation, then 7 weeks of follow-up off the drug.

The results

The FDA label reports these week-64 results for everyone randomized (the intention-to-treat analysis):

Outcome at week 64	Placebo (n=102)	Wegovy 25 mg tablet (n=205)
Average change in body weight	-2.4%	-13.6%
Lost at least 5% of body weight	31.3%	76.3%
Lost at least 10%	14.4%	59.8%
Lost at least 15%	5.5%	47%
Lost at least 20%	3.1%	27.9%

The label also reports an average waist reduction of 12.2 cm on the pill versus 2.8 cm on placebo.

You may see two other numbers quoted. The NEJM paper reports placebo at -2.2% using its own statistical model. And Novo Nordisk’s announcement highlights 16.6%, which is the “trial product estimand”: an estimate of what happens if everyone keeps taking the drug as directed. The 13.6% figure includes people who stopped treatment, so it is closer to a real-world average. Both are legitimate; they answer different questions.

How does that compare with the injection?

For the Wegovy 2.4 mg injection, the label’s main 68-week trial in adults without diabetes (STEP 1, listed as Study 2) shows an average 14.9% loss versus 2.4% on placebo. Those are different trials with different lengths and participants, so they are not a head-to-head comparison. The label does say that in people without type 2 diabetes, average blood levels of semaglutide are similar with the 25 mg tablet and the 2.4 mg weekly injection, but they vary more from person to person with the tablet.

That variability matters most in type 2 diabetes. The label says that people with type 2 diabetes had lower average semaglutide levels on the tablet than on the injection, that the tablet has not been studied for weight reduction in people with type 2 diabetes, and that clinicians can consider switching to the injection if someone with diabetes does not respond well. (Semaglutide is generally less effective for weight loss in people with type 2 diabetes in either form.)

For a deeper look at the injection trials, see our Semaglutide hub.

Side effects and safety

Because it is the same drug, oral semaglutide shares the injection’s safety profile, and the label covers both forms together.

Common side effects

Digestive effects dominate. In OASIS 4, 74.0% of people on the pill reported gastrointestinal adverse events, versus 42.2% on placebo. The label says the types and frequency of common side effects with the 25 mg tablet were similar to the injection, where the most common are nausea, diarrhea, vomiting, constipation and abdominal pain, plus headache and fatigue.

A Novo Nordisk analysis of OASIS 4 presented at the 2026 European Congress on Obesity reported that these effects were typically mild to moderate and temporary, and that none were classed as serious.

A few tablet-specific numbers from the label:

• Stopping because of side effects: 6.9% on the tablet versus 5.9% on placebo; digestive side effects were the most common reason (3.4% versus 2%).
• Severe digestive reactions: 2% on the tablet versus 0% on placebo.
• Gallstones (cholelithiasis): 2.5% on the tablet versus 1% on placebo.
• Dysesthesia (unusual skin sensations such as tingling or burning): 5% on the tablet versus none on placebo.

For practical, evidence-based ways to handle nausea, see GLP-1 nausea: why it happens and how to manage it and our side-effects guide.

Serious risks and warnings

The Wegovy label, for both pill and injection, includes:

• a boxed warning about thyroid C-cell tumors seen in rodents (whether this applies to humans is unknown); semaglutide must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2 syndrome,
• warnings about pancreatitis, gallbladder disease, low blood sugar in people on other diabetes medicines, kidney problems from dehydration, allergic reactions, and other risks listed in the label,
• a recommendation to stop the drug at least 2 months before a planned pregnancy, because semaglutide stays in the body for weeks.

Two tablet-specific cautions

Breastfeeding. The label says breastfeeding is not recommended while taking the Wegovy pill. That is not mainly about semaglutide: a lactation study found semaglutide below measurable levels in breast milk, but SNAC and its breakdown products do reach breast milk, and infants may clear SNAC more slowly. Because SNAC-free semaglutide formulations exist, the label points to those instead.

Other morning pills. Semaglutide slows stomach emptying, which can change how other oral medicines are absorbed. In a label interaction study, levothyroxine exposure rose 33% when taken with the semaglutide tablet. The label advises monitoring medicines taken alongside it, especially ones where small changes in blood level matter. If you take thyroid medicine or other daily morning pills, this is a conversation to have with your prescriber and pharmacist before you start.

Pill or injection: how people decide

Neither form is “better” for everyone. These are the trade-offs that come up most often in a clinician’s office:

• Needles. For people who dislike or cannot manage injections, a pill removes that barrier.
• Routine. The weekly pen is taken once a week at any time of day, with or without food. The pill is daily, with a strict empty-stomach routine. Some people find a daily habit easier to remember; others find the 30-minute wait hard to sustain.
• Other medicines. People who take several morning medicines may find the timing rules awkward.
• Diabetes. Because of the blood-level differences in the label, people with type 2 diabetes have extra factors to discuss.
• Storage and travel. Tablets come in bottles of 30. Pens have their own storage instructions; check the label for each.
• Switching. The label describes how to move between forms. For example, it says people on the 2.4 mg injection can start the 25 mg tablet one week after their last injection, and people on the 25 mg tablet can start the 2.4 mg weekly injection the day after their last tablet. Never switch on your own.
• Cost. See below.

Oral semaglutide vs other GLP-1 pills

“GLP-1 pill” now covers more than one product, and the differences matter:

• Wegovy pill (oral semaglutide 25 mg): a peptide that needs SNAC and strict empty-stomach dosing. Approved for weight management and cardiovascular risk reduction.
• Rybelsus (oral semaglutide): the same technology, at lower doses, for type 2 diabetes only.
• Foundayo (orforglipron): approved in April 2026. It is a non-peptide, small-molecule GLP-1 receptor agonist, so it does not need an absorption enhancer. Its label says to take it once daily with or without food.

The FDA label for Wegovy also says it should not be combined with other semaglutide products or any other GLP-1 receptor agonist. For the full list of approved options, see which GLP-1 medications are FDA-approved for weight loss, and for the whole category, our Oral & New GLP-1s hub.

What about compounded “oral semaglutide”?

You may see compounded semaglutide sold as tablets, drops or dissolving forms online. These are not FDA-approved. FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed, and that compounded drugs should only be used when a patient’s medical needs cannot be met by an FDA-approved drug.

There is also a scientific reason for caution. The Wegovy pill’s results come from a specific tablet that pairs semaglutide with SNAC in a precise way; the 2018 absorption research found that absorption depended on that co-formulation. A different formulation cannot be assumed to deliver the same amount of drug. FDA has also warned that some compounders use salt forms such as semaglutide sodium or semaglutide acetate, which are different active ingredients from the approved drug and for which FDA knows of no lawful basis for use in compounding.

If you are considering an online program, our guide to how telehealth weight-loss programs work covers FDA’s red flags and the questions to ask.

What does the Wegovy pill cost without insurance?

As checked in October 2026, NovoCare Pharmacy (Novo Nordisk’s direct pharmacy) lists self-pay prices for the Wegovy pill of $149 a month at 1.5 mg, $199 at 4 mg, and $299 at 9 mg or 25 mg, with one month defined as a bottle of 30 tablets. It also lists a savings offer for eligible commercially insured patients of as little as $25 a month, excluding people with government insurance. The company says these programs can change at any time, so check current terms. A prescription is always required, and clinician or program fees are separate.

For the full breakdown, including injection prices, see semaglutide cost without insurance and our GLP-1 cost guide.

Habits still matter

Both Wegovy forms are approved for use alongside a reduced-calorie diet and increased physical activity. Eating less makes protein and resistance exercise more important for protecting muscle. See how much protein you need on a GLP-1 and strength training on GLP-1s.

What people are asking online

On X, recent posts about the Wegovy pill are dominated by prescription-tracking charts, launch news in other countries and debates comparing it with Foundayo on side effects and weight loss. Those discussions show how much interest there is in GLP-1 pills, but social posts are not medical evidence: some mix up trial estimands, compare different trials as if they were head-to-head, or confuse orforglipron with tirzepatide. When a post makes a clinical claim, check it against the FDA label linked below.

The bottom line

Oral semaglutide is the same GLP-1 medicine as the weekly injection, made swallowable by an absorption enhancer that briefly helps it through the stomach lining. That design is why the Wegovy pill comes with a precise morning routine: empty stomach, a little plain water, swallow whole, then wait at least 30 minutes. In the OASIS 4 trial, average weight loss was in the same range reported for the injection, with a similar pattern of mostly digestive side effects. The pill’s absorption varies more between people, it is not recommended while breastfeeding, and it can affect other morning medicines, so it is best chosen together with a clinician who knows your full medication list.

Explore more in the Oral & New GLP-1s hub, the Semaglutide hub and the GLP-1 Guide.

Medical disclaimer: Weightomics publishes general health information for education only. It is not a substitute for professional medical advice, diagnosis or treatment. Never start, stop or change a medication without talking to a licensed clinician. Weightomics does not endorse any product, pharmacy or program mentioned in this article.